Law360, New York (October 21, 2013, 2:20 PM EDT) -- The U.S. Supreme Court on Monday rejected Novo Nordisk A/S' request that the high court review an Oregon state court's decision to assert jurisdiction over the company in a suit alleging its hormone therapy drug Activella caused a case of breast cancer.
The denial is a setback for Novo Nordisk, which had argued that the Circuit Court of Multnomah County, Ore., in violation of the company's constitutional due process rights, had incorrectly held that it had personal jurisdiction over the Danish drugmaker under a "stream of commerce" theory for Activella sold by a subsidiary, despite having no direct connection to the state....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!